Clinical trials: IDH Wildtype Glioblastoma
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma.
- Trial name
- NCT07452458
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 54 sites in United States
- Volunteers
- 398 people
- Sponsor
- NRG Oncology
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT06410248
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Northwestern University
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Niacin in Glioblastoma
This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy…
- Trial name
- NCT04677049
- Testing
- Niacin CRT
- Where
- Canada
- Volunteers
- 59 people
- Sponsor
- AHS Cancer Control Alberta
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study
This prospective, interventional, monocentric study will aim at investigating the relationship between pesticide exposure and the treatment response of patients with GBM.
- Trial name
- EXPOGLIO (NCT07788430)
- Testing
- Biological sample collection, Self-reported questionnaire
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Claudius Regaud
Glioblastoma, IDH-Wildtype
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma.
- Trial name
- GABLE (NCT06319027)
- Testing
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival.
- Trial name
- NCT07091864
- Testing
- Best Practice, Biospecimen Collection, Dietary Intervention
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- Mayo Clinic
Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype
WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous…
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System
- Trial name
- NCT04197934
- Testing
- Biospecimen Collection - blood samples, Biospecimen Collection - CSF samples, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma.
- Trial name
- NCT05879250
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Northwestern University
Recurrent Glioblastoma IDH Wildtype, Recurrent Glioblastoma
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
This study is testing a new way of treating brain tumours using tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres). These microspheres are placed into the blood vessels that feed the tumour.
- Trial name
- PRECISE (NCT07712770)
- Testing
- SIR-Spheres®
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas.
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype
- Trial name
- NCT04623931
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
IDH-Wildtype Glioblastoma, Glioblastoma (GBM)
The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle.
- Trial name
- TMZ-CHRONO (NCT06850766)
- Testing
- Morning administration of TMZ, Evening administration of TMZ
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Glioma, Glioma (Diagnosis)
GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-GBM can help detect a specific molecular type of brain tumour called IDH wildtype glioblastoma using routine MRI scans.
- Conditions
- Glioma, Glioma (Diagnosis), Glioblastom WHO Grade 4, IDH Wildtype Glioblastoma
- Trial name
- GliomaAI-GBM (NCT07673692)
- Testing
- GliomaAI-GBM
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult
- Trial name
- NCT07668869
- Testing
- Tumor Treating Fields (TTFields), FET-PET-Guided Stereotactic Radiosurgery
- Where
- Poland
- Volunteers
- 92 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Recurrent High-Grade Gliomas, Recurrent Glioblastoma IDH Wildtype
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, [177Lu]Lu-DOTA-EB-RGD2, in patients with…
- Trial name
- NCT07655869
- Testing
- [177Lu]Lu-DOTA-EB-RGD2
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Beijing Tiantan Hospital
Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer.
- Conditions
- Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH Wildtype
- Trial name
- NCT07648823
- Testing
- [177Lu]Lu-XT771
- Where
- 2 sites in China
- Volunteers
- 5 people
- Sponsor
- Beijing Tiantan Hospital
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase I trial studies the side effects and best dose of Actimab-A when given together with cemiplimab (REGN2810) in treating patients with glioblastomas that have come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT07422363
- Testing
- Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
A Study of 177Lu-PSMA-617 in People With Gliomas
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT07223034
- Testing
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center